EMEA (Europe, Middle East and Africa) Granulomatosis with Polyangiitis Drug Market Report 2018

February 2018 | 105 pages | ID: E0DB6C99D17EN
QYResearch

Abstracts

In this report, the EMEA Granulomatosis with Polyangiitis Drug market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Granulomatosis with Polyangiitis Drug for these regions, from 2013 to 2025 (forecast)

• Europe: Germany, France, UK, Russia, Italy and Benelux;
• Middle East: Saudi Arabia, Israel, UAE and Iran;
• Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Granulomatosis with Polyangiitis Drug market competition by top manufacturers/players, with Granulomatosis with Polyangiitis Drug sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including

• Bionovis SA
• Bristol-Myers Squibb Company
• ChemoCentryx Inc
• Coherus BioSciences Inc
• Genor BioPharma Co Ltd
• GlaxoSmithKline Plc
• Iltoo Pharma
• Panacea Biotec Ltd
• Sandoz International GmbH
• The International Biotechnology Center (IBC) Generium

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

• Benralizumab
• Avacopan
• Rituximab Biosimilar
• Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Hospital
• Clinic
• Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

EMEA (Europe, Middle East and Africa) Granulomatosis with Polyangiitis Drug Market Report 2018

1 GRANULOMATOSIS WITH POLYANGIITIS DRUG OVERVIEW

1.1 Product Overview and Scope of Granulomatosis with Polyangiitis Drug
1.2 Classification of Granulomatosis with Polyangiitis Drug
  1.2.1 EMEA Granulomatosis with Polyangiitis Drug Market Size (Sales) Comparison by Type (2013-2025)
  1.2.2 EMEA Granulomatosis with Polyangiitis Drug Market Size (Sales) Market Share by Type (Product Category) in 2017
  1.2.3 Benralizumab
  1.2.4 Avacopan
  1.2.5 Rituximab Biosimilar
  1.2.6 Others
1.3 EMEA Granulomatosis with Polyangiitis Drug Market by Application/End Users
  1.3.1 EMEA Granulomatosis with Polyangiitis Drug Sales (Volume) and Market Share Comparison by Application (2013-2025)
  1.3.2 Hospital
  1.3.3 Clinic
  1.3.4 Others
1.4 EMEA Granulomatosis with Polyangiitis Drug Market by Region
  1.4.1 EMEA Granulomatosis with Polyangiitis Drug Market Size (Value) Comparison by Region (2013-2025)
  1.4.2 Europe Status and Prospect (2013-2025)
  1.4.3 Middle East Status and Prospect (2013-2025)
  1.4.4 Africa Status and Prospect (2013-2025)
1.5 EMEA Market Size (Value and Volume) of Granulomatosis with Polyangiitis Drug (2013-2025)
  1.5.1 EMEA Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2013-2025)
  1.5.2 EMEA Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2013-2025)

2 EMEA GRANULOMATOSIS WITH POLYANGIITIS DRUG COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA Granulomatosis with Polyangiitis Drug Market Competition by Players/Manufacturers
  2.1.1 EMEA Granulomatosis with Polyangiitis Drug Sales Volume and Market Share of Major Players (2013-2018)
  2.1.2 EMEA Granulomatosis with Polyangiitis Drug Revenue and Share by Players (2013-2018)
  2.1.3 EMEA Granulomatosis with Polyangiitis Drug Sale Price by Players (2013-2018)
2.2 EMEA Granulomatosis with Polyangiitis Drug (Volume and Value) by Type/Product Category
  2.2.1 EMEA Granulomatosis with Polyangiitis Drug Sales and Market Share by Type (2013-2018)
  2.2.2 EMEA Granulomatosis with Polyangiitis Drug Revenue and Market Share by Type (2013-2018)
  2.2.3 EMEA Granulomatosis with Polyangiitis Drug Sale Price by Type (2013-2018)
2.3 EMEA Granulomatosis with Polyangiitis Drug (Volume) by Application
2.4 EMEA Granulomatosis with Polyangiitis Drug (Volume and Value) by Region
  2.4.1 EMEA Granulomatosis with Polyangiitis Drug Sales and Market Share by Region (2013-2018)
  2.4.2 EMEA Granulomatosis with Polyangiitis Drug Revenue and Market Share by Region (2013-2018)
  2.4.3 EMEA Granulomatosis with Polyangiitis Drug Sales Price by Region (2013-2018)

3 EUROPE GRANULOMATOSIS WITH POLYANGIITIS DRUG (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

3.1 Europe Granulomatosis with Polyangiitis Drug Sales and Value (2013-2018)
  3.1.1 Europe Granulomatosis with Polyangiitis Drug Sales Volume and Growth Rate (2013-2018)
  3.1.2 Europe Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2013-2018)
3.2 Europe Granulomatosis with Polyangiitis Drug Sales and Market Share by Type
3.3 Europe Granulomatosis with Polyangiitis Drug Sales and Market Share by Application
3.4 Europe Granulomatosis with Polyangiitis Drug Sales Volume and Value (Revenue) by Countries
  3.4.1 Europe Granulomatosis with Polyangiitis Drug Sales Volume by Countries (2013-2018)
  3.4.2 Europe Granulomatosis with Polyangiitis Drug Revenue by Countries (2013-2018)
  3.4.3 Germany Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2013-2018)
  3.4.4 France Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2013-2018)
  3.4.5 UK Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2013-2018)
  3.4.6 Russia Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2013-2018)
  3.4.7 Italy Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2013-2018)
  3.4.8 Benelux Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2013-2018)

4 MIDDLE EAST GRANULOMATOSIS WITH POLYANGIITIS DRUG (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

4.1 Middle East Granulomatosis with Polyangiitis Drug Sales and Value (2013-2018)
  4.1.1 Middle East Granulomatosis with Polyangiitis Drug Sales Volume and Growth Rate (2013-2018)
  4.1.2 Middle East Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2013-2018)
4.2 Middle East Granulomatosis with Polyangiitis Drug Sales and Market Share by Type
4.3 Middle East Granulomatosis with Polyangiitis Drug Sales and Market Share by Application
4.4 Middle East Granulomatosis with Polyangiitis Drug Sales Volume and Value (Revenue) by Countries
  4.4.1 Middle East Granulomatosis with Polyangiitis Drug Sales Volume by Countries (2013-2018)
  4.4.2 Middle East Granulomatosis with Polyangiitis Drug Revenue by Countries (2013-2018)
  4.4.3 Saudi Arabia Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2013-2018)
  4.4.4 Israel Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2013-2018)
  4.4.5 UAE Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2013-2018)
  4.4.6 Iran Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2013-2018)

5 AFRICA GRANULOMATOSIS WITH POLYANGIITIS DRUG (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

5.1 Africa Granulomatosis with Polyangiitis Drug Sales and Value (2013-2018)
  5.1.1 Africa Granulomatosis with Polyangiitis Drug Sales Volume and Growth Rate (2013-2018)
  5.1.2 Africa Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2013-2018)
5.2 Africa Granulomatosis with Polyangiitis Drug Sales and Market Share by Type
5.3 Africa Granulomatosis with Polyangiitis Drug Sales and Market Share by Application
5.4 Africa Granulomatosis with Polyangiitis Drug Sales Volume and Value (Revenue) by Countries
  5.4.1 Africa Granulomatosis with Polyangiitis Drug Sales Volume by Countries (2013-2018)
  5.4.2 Africa Granulomatosis with Polyangiitis Drug Revenue by Countries (2013-2018)
  5.4.3 South Africa Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2013-2018)
  5.4.4 Nigeria Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2013-2018)
  5.4.5 Egypt Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2013-2018)
  5.4.6 Algeria Granulomatosis with Polyangiitis Drug Sales and Growth Rate (2013-2018)

6 EMEA GRANULOMATOSIS WITH POLYANGIITIS DRUG MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

6.1 Bionovis SA
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Granulomatosis with Polyangiitis Drug Product Type, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Bionovis SA Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.1.4 Main Business/Business Overview
6.2 Bristol-Myers Squibb Company
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Granulomatosis with Polyangiitis Drug Product Type, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.2.4 Main Business/Business Overview
6.3 ChemoCentryx Inc
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 Granulomatosis with Polyangiitis Drug Product Type, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.3.4 Main Business/Business Overview
6.4 Coherus BioSciences Inc
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 Granulomatosis with Polyangiitis Drug Product Type, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.4.4 Main Business/Business Overview
6.5 Genor BioPharma Co Ltd
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 Granulomatosis with Polyangiitis Drug Product Type, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.5.4 Main Business/Business Overview
6.6 GlaxoSmithKline Plc
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Granulomatosis with Polyangiitis Drug Product Type, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.6.4 Main Business/Business Overview
6.7 Iltoo Pharma
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 Granulomatosis with Polyangiitis Drug Product Type, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.7.4 Main Business/Business Overview
6.8 Panacea Biotec Ltd
  6.8.1 Company Basic Information, Manufacturing Base and Competitors
  6.8.2 Granulomatosis with Polyangiitis Drug Product Type, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.8.4 Main Business/Business Overview
6.9 Sandoz International GmbH
  6.9.1 Company Basic Information, Manufacturing Base and Competitors
  6.9.2 Granulomatosis with Polyangiitis Drug Product Type, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.9.4 Main Business/Business Overview
6.10 The International Biotechnology Center (IBC) Generium
  6.10.1 Company Basic Information, Manufacturing Base and Competitors
  6.10.2 Granulomatosis with Polyangiitis Drug Product Type, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin (2013-2018)
  6.10.4 Main Business/Business Overview

7 GRANULOMATOSIS WITH POLYANGIITIS DRUG MANUFACTURING COST ANALYSIS

7.1 Granulomatosis with Polyangiitis Drug Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Granulomatosis with Polyangiitis Drug

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Granulomatosis with Polyangiitis Drug Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Granulomatosis with Polyangiitis Drug Major Manufacturers in 2017
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 EMEA GRANULOMATOSIS WITH POLYANGIITIS DRUG MARKET FORECAST (2018-2025)

11.1 EMEA Granulomatosis with Polyangiitis Drug Sales, Revenue and Price Forecast (2018-2025)
  11.1.1 EMEA Granulomatosis with Polyangiitis Drug Sales and Growth Rate Forecast (2018-2025)
  11.1.2 EMEA Granulomatosis with Polyangiitis Drug Revenue and Growth Rate Forecast (2018-2025)
  11.1.3 EMEA Granulomatosis with Polyangiitis Drug Price and Trend Forecast (2018-2025)
11.2 EMEA Granulomatosis with Polyangiitis Drug Sales, Revenue and Growth Rate Forecast by Region (2018-2025)
11.3 Europe Granulomatosis with Polyangiitis Drug Sales, Revenue and Growth Rate Forecast by Region (2018-2025)
11.4 Middle Eastt Granulomatosis with Polyangiitis Drug Sales, Revenue and Growth Rate Forecast by Region (2018-2025)
11.5 Africa Granulomatosis with Polyangiitis Drug Sales, Revenue and Growth Rate Forecast by Region (2018-2025)
11.6 EMEA Granulomatosis with Polyangiitis Drug Sales Forecast by Type (2018-2025)
11.7 EMEA Granulomatosis with Polyangiitis Drug Sales Forecast by Application (2018-2025)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Granulomatosis with Polyangiitis Drug
Figure EMEA Granulomatosis with Polyangiitis Drug Sales Volume (K Pcs) by Type (2013-2025)
Figure EMEA Granulomatosis with Polyangiitis Drug Sales Volume Market Share by Type (Product Category) in 2017
Figure Benralizumab Product Picture
Figure Avacopan Product Picture
Figure Rituximab Biosimilar Product Picture
Figure Others Product Picture
Figure EMEA Granulomatosis with Polyangiitis Drug Sales Volume (K Pcs) by Application (2013-2025)
Figure EMEA Sales Market Share of Granulomatosis with Polyangiitis Drug by Application in 2017
Figure Hospital Examples
Table Key Downstream Customer in Hospital
Figure Clinic Examples
Table Key Downstream Customer in Clinic
Figure Others Examples
Table Key Downstream Customer in Others
Figure EMEA Granulomatosis with Polyangiitis Drug Market Size (Million USD) by Region (2013-2025)
Figure Europe Granulomatosis with Polyangiitis Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure Europe Granulomatosis with Polyangiitis Drug Revenue (Million USD) Status and Forecast by Countries
Figure Middle East Granulomatosis with Polyangiitis Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure Middle East Granulomatosis with Polyangiitis Drug Revenue (Million USD) Status and Forecast by Countries
Figure Africa Granulomatosis with Polyangiitis Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure Africa Granulomatosis with Polyangiitis Drug Revenue (Million USD) Status and Forecast by Countries
Figure EMEA Granulomatosis with Polyangiitis Drug Sales Volume and Growth Rate (2013-2025)
Figure EMEA Granulomatosis with Polyangiitis Drug Revenue (Million USD) and Growth Rate (2013-2025)
Figure EMEA Granulomatosis with Polyangiitis Drug Market Major Players Product Sales Volume (K Pcs) (2013-2018)
Table EMEA Granulomatosis with Polyangiitis Drug Sales Volume (K Pcs) of Major Players (2013-2018)
Table EMEA Granulomatosis with Polyangiitis Drug Sales Share by Players (2013-2018)
Figure 2017 Granulomatosis with Polyangiitis Drug Sales Share by Players
Figure 2017 Granulomatosis with Polyangiitis Drug Sales Share by Players
Figure EMEA Granulomatosis with Polyangiitis Drug Market Major Players Product Revenue (Million USD) (2013-2018)
Table EMEA Granulomatosis with Polyangiitis Drug Revenue (Million USD) by Players (2013-2018)
Table EMEA Granulomatosis with Polyangiitis Drug Revenue Share by Players (2013-2018)
Table 2017 EMEA Granulomatosis with Polyangiitis Drug Revenue Share by Players
Table 2017 EMEA Granulomatosis with Polyangiitis Drug Revenue Share by Players
Table EMEA Granulomatosis with Polyangiitis Drug Sale Price (USD/Pcs) by Players (2013-2018)
Table EMEA Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Market Share by Type (2013-2018)
Table EMEA Granulomatosis with Polyangiitis Drug Sales Share by Type (2013-2018)
Figure Sales Market Share of Granulomatosis with Polyangiitis Drug by Type (2013-2018)
Figure EMEA Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2013-2018)
Table EMEA Granulomatosis with Polyangiitis Drug Revenue (Million USD) and Market Share by Type (2013-2018)
Table EMEA Granulomatosis with Polyangiitis Drug Revenue Share by Type (2013-2018)
Figure Revenue Market Share of Granulomatosis with Polyangiitis Drug by Type in 2017
Table EMEA Granulomatosis with Polyangiitis Drug Sale Price (USD/Pcs) by Type (2013-2018)
Table EMEA Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Market Share by Application (2013-2018)
Table EMEA Granulomatosis with Polyangiitis Drug Sales Share by Application (2013-2018)
Figure Sales Market Share of Granulomatosis with Polyangiitis Drug by Application (2013-2018)
Figure EMEA Granulomatosis with Polyangiitis Drug Sales Market Share by Application in 2017
Table EMEA Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Market Share by Region (2013-2018)
Table EMEA Granulomatosis with Polyangiitis Drug Sales Share by Region (2013-2018)
Figure Sales Market Share of Granulomatosis with Polyangiitis Drug by Region (2013-2018)
Figure EMEA Granulomatosis with Polyangiitis Drug Sales Market Share in 2017
Table EMEA Granulomatosis with Polyangiitis Drug Revenue (Million USD) and Market Share by Region (2013-2018)
Table EMEA Granulomatosis with Polyangiitis Drug Revenue Share by Region (2013-2018)
Figure Revenue Market Share of Granulomatosis with Polyangiitis Drug by Region (2013-2018)
Figure EMEA Granulomatosis with Polyangiitis Drug Revenue Market Share Regions in 2017
Table EMEA Granulomatosis with Polyangiitis Drug Sales Price (USD/Pcs) by Region (2013-2018)
Figure Europe Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Europe Granulomatosis with Polyangiitis Drug Revenue and Growth Rate (2013-2018)
Table Europe Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Type (2013-2018)
Table Europe Granulomatosis with Polyangiitis Drug Market Share by Type (2013-2018)
Figure Europe Granulomatosis with Polyangiitis Drug Market Share by Type in 2017
Table Europe Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Application (2013-2018)
Table Europe Granulomatosis with Polyangiitis Drug Market Share by Application (2013-2018)
Figure Europe Granulomatosis with Polyangiitis Drug Market Share by Application in 2017
Table Europe Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Countries (2013-2018)
Table Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Countries (2013-2018)
Figure Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Countries (2013-2018)
Figure Europe Granulomatosis with Polyangiitis Drug Sales Market Share by Countries in 2017
Table Europe Granulomatosis with Polyangiitis Drug Revenue (Million USD) by Countries (2013-2018)
Table Europe Granulomatosis with Polyangiitis Drug Revenue Market Share by Countries (2013-2018)
Figure Europe Granulomatosis with Polyangiitis Drug Revenue Market Share by Countries (2013-2018)
Figure Europe Granulomatosis with Polyangiitis Drug Revenue Market Share by Countries in 2017
Figure Germany Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure France Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure UK Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Russia Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Italy Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Benelux Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Middle East Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Middle East Granulomatosis with Polyangiitis Drug Revenue (Million USD) and Growth Rate (2013-2018)
Table Middle East Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Type (2013-2018)
Table Middle East Granulomatosis with Polyangiitis Drug Market Share by Type (2013-2018)
Figure Middle East Granulomatosis with Polyangiitis Drug Market Share by Type (2013-2018)
Table Middle East Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Applications (2013-2018)
Table Middle East Granulomatosis with Polyangiitis Drug Market Share by Applications (2013-2018)
Figure Middle East Granulomatosis with Polyangiitis Drug Sales Market Share by Application in 2017
Table Middle East Granulomatosis with Polyangiitis Drug Sales Volume (K Pcs) by Countries (2013-2018)
Table Middle East Granulomatosis with Polyangiitis Drug Sales Volume Market Share by Countries (2013-2018)
Figure Middle East Granulomatosis with Polyangiitis Drug Sales Volume Market Share by Countries in 2017
Table Middle East Granulomatosis with Polyangiitis Drug Revenue (Million USD) by Countries (2013-2018)
Table Middle East Granulomatosis with Polyangiitis Drug Revenue Market Share by Countries (2013-2018)
Figure Middle East Granulomatosis with Polyangiitis Drug Revenue Market Share by Countries (2013-2018)
Figure Middle East Granulomatosis with Polyangiitis Drug Revenue Market Share by Countries in 2017
Figure Saudi Arabia Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Israel Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure UAE Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Iran Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Africa Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Africa Granulomatosis with Polyangiitis Drug Revenue (Million USD) and Growth Rate (2013-2018)
Table Africa Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Type (2013-2018)
Table Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2013-2018)
Figure Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Type (2013-2018)
Figure Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Type in 2017
Table Africa Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Application (2013-2018)
Table Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2013-2018)
Figure Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Application (2013-2018)
Table Africa Granulomatosis with Polyangiitis Drug Sales Volume (K Pcs) by Countries (2013-2018)
Table Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Countries (2013-2018)
Figure Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Countries (2013-2018)
Figure Africa Granulomatosis with Polyangiitis Drug Sales Market Share by Countries in 2017
Table Africa Granulomatosis with Polyangiitis Drug Revenue (Million USD) by Countries (2013-2018)
Table Africa Granulomatosis with Polyangiitis Drug Revenue Market Share by Countries (2013-2018)
Figure Africa Granulomatosis with Polyangiitis Drug Revenue Market Share by Countries (2013-2018)
Figure Africa Granulomatosis with Polyangiitis Drug Revenue Market Share by Countries in 2017
Figure South Africa Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Nigeria Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Egypt Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Algeria Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Table Bionovis SA Granulomatosis with Polyangiitis Drug Basic Information List
Table Bionovis SA Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Bionovis SA Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Bionovis SA Granulomatosis with Polyangiitis Drug Sales Market Share in EMEA (2013-2018)
Figure Bionovis SA Granulomatosis with Polyangiitis Drug Revenue Market Share in EMEA (2013-2018)
Table Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Basic Information List
Table Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales Market Share in EMEA (2013-2018)
Figure Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Revenue Market Share in EMEA (2013-2018)
Table ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Basic Information List
Table ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales Market Share in EMEA (2013-2018)
Figure ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Revenue Market Share in EMEA (2013-2018)
Table Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Basic Information List
Table Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales Market Share in EMEA (2013-2018)
Figure Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Revenue Market Share in EMEA (2013-2018)
Table Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Basic Information List
Table Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales Market Share in EMEA (2013-2018)
Figure Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Revenue Market Share in EMEA (2013-2018)
Table GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Basic Information List
Table GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales Market Share in EMEA (2013-2018)
Figure GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Revenue Market Share in EMEA (2013-2018)
Table Iltoo Pharma Granulomatosis with Polyangiitis Drug Basic Information List
Table Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales Market Share in EMEA (2013-2018)
Figure Iltoo Pharma Granulomatosis with Polyangiitis Drug Revenue Market Share in EMEA (2013-2018)
Table Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Basic Information List
Table Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales Market Share in EMEA (2013-2018)
Figure Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Revenue Market Share in EMEA (2013-2018)
Table Sandoz International GmbH Granulomatosis with Polyangiitis Drug Basic Information List
Table Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales Market Share in EMEA (2013-2018)
Figure Sandoz International GmbH Granulomatosis with Polyangiitis Drug Revenue Market Share in EMEA (2013-2018)
Table The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Basic Information List
Table The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2013-2018)
Figure The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate (2013-2018)
Figure The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales Market Share in EMEA (2013-2018)
Figure The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Revenue Market Share in EMEA (2013-2018)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Granulomatosis with Polyangiitis Drug
Figure Manufacturing Process Analysis of Granulomatosis with Polyangiitis Drug
Figure Granulomatosis with Polyangiitis Drug Industrial Chain Analysis
Table Raw Materials Sources of Granulomatosis with Polyangiitis Drug Major Manufacturers in 2017
Table Major Buyers of Granulomatosis with Polyangiitis Drug
Table Distributors/Traders List
Figure EMEA Granulomatosis with Polyangiitis Drug Sales (K Pcs) and Growth Rate Forecast (2018-2025)
Figure EMEA Granulomatosis with Polyangiitis Drug Revenue and Growth Rate Forecast (2018-2025)
Figure EMEA Granulomatosis with Polyangiitis Drug Price (USD/Pcs) and Trend Forecast (2018-2025)
Table EMEA Granulomatosis with Polyangiitis Drug Sales (K Pcs) Forecast by Region (2018-2025)
Figure EMEA Granulomatosis with Polyangiitis Drug Sales Market Share Forecast by Region (2018-2025)
Table EMEA Granulomatosis with Polyangiitis Drug Revenue (Million USD) Forecast by Region (2018-2025)
Figure EMEA Granulomatosis with Polyangiitis Drug Revenue Market Share Forecast by Region (2018-2025)
Table Europe Granulomatosis with Polyangiitis Drug Sales (K Pcs) Forecast by Countries (2018-2025)
Figure Europe Granulomatosis with Polyangiitis Drug Sales Market Share Forecast by Countries (2018-2025)
Table Europe Granulomatosis with Polyangiitis Drug Revenue (Million USD) Forecast by Countries (2018-2025)
Figure Europe Granulomatosis with Polyangiitis Drug Revenue Market Share Forecast by Countries (2018-2025)
Table Middle East Granulomatosis with Polyangiitis Drug Sales (K Pcs) Forecast by Countries (2018-2025)
Figure Middle East Granulomatosis with Polyangiitis Drug Sales Market Share Forecast by Countries (2018-2025)
Table Middle East Granulomatosis with Polyangiitis Drug Revenue (Million USD) Forecast by Countries (2018-2025)
Figure Middle East Granulomatosis with Polyangiitis Drug Revenue Market Share Forecast by Countries (2018-2025)
Table Africa Granulomatosis with Polyangiitis Drug Sales (K Pcs) Forecast by Countries (2018-2025)
Figure Africa Granulomatosis with Polyangiitis Drug Sales Market Share Forecast by Countries (2018-2025)
Table Africa Granulomatosis with Polyangiitis Drug Revenue (Million USD) Forecast by Countries (2018-2025)
Figure Africa Granulomatosis with Polyangiitis Drug Revenue Market Share Forecast by Countries (2018-2025)
Table EMEA Granulomatosis with Polyangiitis Drug Sales (K Pcs) Forecast by Type (2018-2025)
Figure EMEA Granulomatosis with Polyangiitis Drug Sales Market Share Forecast by Type (2018-2025)
Table EMEA Granulomatosis with Polyangiitis Drug Sales (K Pcs) Forecast by Application (2018-2025)
Figure EMEA Granulomatosis with Polyangiitis Drug Sales Market Share Forecast by Application (2018-2025)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources